# Improved Therapy Response Assessment in Metastatic Brain Tumors

> **NCT03458455** · — · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Brain Metastases

## Interventions

- **DIAGNOSTIC_TEST:** Magnetic Resonance Imaging
- **RADIATION:** Stereotactic Radiosurgery
- **DRUG:** Ipilimumab, nivolumab or pembrolizumab

## Key facts

- **NCT ID:** NCT03458455
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03-01
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-11-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03458455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03458455, "Improved Therapy Response Assessment in Metastatic Brain Tumors". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03458455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*